Children’s Hospital LA halts use of Sarepta’s gene therapy for all patients
Children’s Hospital Los Angeles has paused the use of Sarepta Therapeutics’ gene therapy Elevidys for all patients with muscular dystrophy, following recent US Food and Drug Administration (FDA) actions that raised safety concerns. In a statement Monday, Children’s Hospital LA said the pause has been communicated to affected patient families while it awaits any further…